Literature DB >> 6682285

Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum in combination with cyclophosphamide. An E.C.O.G. pilot study.

L Israel, J Aguilera, J L Breau.   

Abstract

Twenty patients with Stage III and IV carcinoma of the ovary have been treated with a combination of cyclophosphamide and cis-platinum given every 3 weeks. Regarding toxicity, this combination probably included a too-high dose of CTX (1.1 g/m2 every 3 weeks). The response rate was 75% (15/20) but with a significant duration only for those patients who achieved a complete response (7/20). It was seen that, as usual, patients who have undergone extensive reductive surgery are more likely to respond. The regimen described gives results comparable to those of more aggressive combinations but did not achieve significant control of the disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682285

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  1 in total

1.  In vitro evaluation of cisplatin interaction with doxorubicin or 4-hydroperoxycyclophosphamide against human gynecologic cancer cell lines.

Authors:  M J Xu; D S Alberts; R Liu; A Leibovitz; Y Liu
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.